We have reported our LGR5-directed antibody drug conjugate (α-LGR5-ADC) in Chen et al. 2004 that was synthesised using a novel linker technology from the laboratory of our collaborator, Dr David Spring (Dept. of Chemistry). α-LGR5-ADC displays fantastic efficacy in targeting LGR5⁺ cancer cells using in vivo cancer models

Our main goal now is to develop α-LGR5-ADC for clinical use.